An Investigational Immuno-therapy Study to Evaluate the Safety and Effectiveness of Experimental Medication BMS-986207 by Itself and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread
Trial Status: Closed to Accrual
The purpose of this study is to evaluate the safety and effectiveness of experimental medication BMS-986207 by itself and in combination with Nivolumab in solid cancers that are advanced or have spread.
Inclusion Criteria
- Women and men ≥18 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Must have received and progressed on or failed one standard/approved treatment for cancer type, if available
- At least 4 weeks since any previous treatment for cancer
- Subject must consent to pretreatment and on treatment tumor biopsies
- At least one lesion with measurable disease at baseline
- Adequate organ and marrow function
Exclusion Criteria
- Patients with primary brain tumors or primary tumors with central nervous system metastases as only location of disease. Controlled brain metastases are permitted
- Prior organ transplant
- Participants with second/other active cancers requiring current treatment
- Uncontrolled/significant heart disease
- History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)
- Active/uncontrolled autoimmune disease
- Active infection
New Jersey
Hackensack
Hackensack University Medical Center
Status: ACTIVE
New York
New York
NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center
Status: CLOSED_TO_ACCRUAL
Pennsylvania
Philadelphia
Fox Chase Cancer Center
Status: ACTIVE
University of Pennsylvania / Abramson Cancer Center
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Status: ACTIVE
Utah
Salt Lake City
Huntsman Cancer Institute / University of Utah
Status: ACTIVE
Trial Phase Phase I/II
Trial Type Treatment
Lead Organization
Bristol-Myers Squibb
- Primary ID CA020-002
- Secondary IDs NCI-2017-00261, 2016-002263-34
- Clinicaltrials.gov ID NCT02913313